ArticleTranslational oncology2026
High SOX17 expression is correlated with favorable prognosis and CD8(+) TILs expression in patients with pancreatic cancer after curative resection.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe SRY-box transcription factor 17 (SOX17) plays a critical role in tumorigenesis and tumor progression and reshaping the tumor immune ecosystem in several cancer types, but its role in pancreatic cancer (PC) remains unknown.
methodsA total of 168 patients with PC who underwent curative resection were consecutively enrolled, and immunohistochemical (IHC) staining was performed, followed by Kaplan-Meier and Cox proportional hazards regression analyses. Meanwhile, specific markers of cancer-associated fibroblasts (CAFs) and tumor-infiltrating lymphocytes (TILs) and PD-L1 expression were detected by IHC staining, and their correlation with SOX17 were evaluated. Finally, single-cell and bulk RNA-seq analyses of public datasets were used to validate the expression profile of SOX17 in PC.
resultsThe Kaplan-Meier curve showed that high SOX17 expression was correlated with a longer overall survival (OS) and disease-free survival (DFS) in patients with PC. Univariate (hazard ratio [HR] = 0.593, P = 0.005 for OS; HR = 0.602, P = 0.012 for DFS) and multivariate (HR = 0.662, P = 0.042 for OS; HR = 0.602, P = 0.036 for DFS) Cox regression analyses demonstrated that high SOX17 expression was an independent favorable prognostic factor. The correlation analysis showed that SOX17 expression was correlated with the expression of CD8+ TILs (P = 0.012) and FAP+ CAFs (P = 0.011). The correlations between SOX17 and CD8+ TILs were validated by multiple algorithms through single-cell and bulk RNA-seq analyses.
conclusionThe present study demonstrates that SOX17 serves as a significant prognostic marker and reflects the tumor immune ecosystem in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.